Republished: Which antibody and which cancer in which paraneoplastic syndromes?

Postgraduate Medical Journal

Volumn 87, Issue 1023, 2011, Pages 60-70

  Gozzard, Paul ^a   Maddison, Paul ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHIPHYSIN; ANTIGEN; CANCER ANTIBODY; CELL ANTIGEN; CHOLINERGIC RECEPTOR; COLLAPSIN RESPONSE MEDIATOR PROTEIN 5; CORTICOSTEROID; IMMUNOGLOBULIN; MEMBRANE ANTIGEN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; ONCONEURAL ANTIBODY; UNCLASSIFIED DRUG; VOLTAGE GATED CALCIUM CHANNEL;

CLINICAL FEATURE; DISEASE ASSOCIATION; HUMAN; IMMUNE RESPONSE; NEOPLASM; PARANEOPLASTIC SYNDROME; PATHOGENESIS; REVIEW;

EID: 78651370033     PISSN: 00325473     EISSN: 14690756     Source Type: Journal    
DOI: 10.1136/jnnp.2010.224105rep     Document Type: Review

References (27)

1. De Angelis LM, 2. Posner JB. Neurologic complications of cancer, 2nd edn. Oxford: Oxford University Press, 2009:577-608.
2. Graus F, 2. Delattre JY, 3. Antoine JC, 4. et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 2004;75:1135-40.
3. Pittock SJ, 2. Kryzer TJ, 3. Lennon VA. Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome. Ann Neurol 2004;56:715-19.
4. Titulaer MJ, 2. Klooster R, 3. Potman M, 4. et al. SOX antibodies in small-cell lung cancer and Lambert - Eaton myasthenic syndrome: frequency and relation with survival. J Clin Oncol 2009;27:4260-7.
5. Smeenk RJ. Antinuclear antibodies: cause of disease or caused by disease? Rheumatology (Oxford) 2000;39:581-4.
6. Tanaka K, 2. Tanaka M, 3. Inuzuka T, 4. et al. Cytotoxic T lymphocyte-mediated cell death in paraneoplastic sensory neuronopathy with anti-Hu antibody. J Neurol Sci 1999;163:159-62.
7. Benyahia B, 2. Liblau R, 3. Merle-Béral H, 4. et al. Cell-mediated autoimmunity in paraneoplastic neurological syndromes with anti-Hu antibodies. Ann Neurol 1999;45:162-7.
8. Rees JH, 2. Hain SF, 3. Johnson MR, 4. et al. The role of [18F]fluoro-2-deoxyglucose-PET scanning in the diagnosis of paraneoplastic neurological disorders. Brain 2001;124(Pt 11):2223-31.
9. Sturgeon CM, 2. Lai LC, 3. Duffy MJ. Serum tumour markers: how to order and interpret them. BMJ 2009;339:b3527.
10. Lucchinetti CF, 2. Kimmel DW, 3. Lennon VA. Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear autoantibodies. Neurology 1998;50:652-7.
11. Peterson K, 2. Rosenblum MK, 3. Kotanides H, 4. et al. Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients. Neurology 1992;42:1931-7.
12. Titulaer MJ, 2. Wirtz PW, 3. Kuks JB, 4. et al. The Lambert - Eaton myasthenic syndrome 1988-2008: a clinical picture in 97 patients. J Neuroimmunol 2008;15;153-8.
13. Douglas CA, 2. Ellershaw J. Anti-Hu antibodies may indicate a positive response to chemotherapy in paraneoplastic syndrome secondary to small-cell lung cancer. Palliat Med 2003;17:638-9.
14. Bernal F, 2. Shams'ili S, 3. Rojas I, 4. et al. Anti-Tr antibodies as markers of paraneoplastic cerebellar degeneration and Hodgkin's disease. Neurology 2003;60:230-4.
15. Keime-Guibert F, 2. Graus F, 3. Broët P, 4. et al. Clinical outcome of patients with anti-Hu-associated encephalomyelitis after treatment of the tumor. Neurology 1999;53:1719-23.
16. Dalmau J, 2. Graus F, 3. Villarejo A, 4. et al. Clinical analysis of anti-Ma2-associated encephalitis. Brain 2004;127(Pt 8):1831-44.
17. Yu Z, 2. Kryzer TJ, 3. Griesmann GE, 4. et al. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol 2001;49:146-54.
18. Pittock SJ, 2. Lucchinetti CF, 3. Parisi JE, 4. et al. Amphiphysin autoimmunity: paraneoplastic accompaniments. Ann Neurol 2005;58:96-107.
19. Pittock SJ, 2. Lucchinetti CF, 3. Lennon VA. Antineuronal nuclear autoantibody type 2: paraneoplastic accompaniments. Ann Neurol 2003;53:580-7.
20. Dalmau J, 2. Gleichman AJ, 3. Hughes EG, 4. et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008;7:1091-8.
21. Tan KM, 2. Lennon VA, 3. Klein CJ, 4. et al. Clinical spectrum of voltage-gated potassium channel autoimmunity. Neurology 2008;70:1883-90.
22. Vernino S, 2. Lennon VA. Autoantibody profiles and neurological correlations of thymoma. Clin Cancer Res 2004;10:7270-5.
23. Wirtz PW, 2. Nijnuis MG, 3. Sotodeh M, 4. et al. ; Dutch Myasthenia Study Group. The epidemiology of myasthenia gravis, Lambert - Eaton myasthenic syndrome and their associated tumours in the northern part of the province of South Holland. J Neurol 2003;250:698-701.
24. Motomura M, 2. Lang B, 3. Johnston I, 4. et al. Incidence of serum anti-P/O-type and anti-N-type calcium channel autoantibodies in the Lambert - Eaton myasthenic syndrome. J Neurol Sci 1997;147:35-42.
25. Irani SR, 2. Alexander S, 3. Waters P, 4. et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain 2010 Epub ahead of print 27 July 2010.
26. Willcox N. Myasthenia gravis. Curr Opin Immunol 1993;5:910-7.
27. Irani SR, 2. Alexander S, 3. Waters P, 4. et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain 2010;133(Pt 9):2734-48.